Navigation Links
Results in Phase I trial of OMP-54F28, a Wnt inhibitor targeting cancer stem cells
Date:5/31/2014

At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials are now open for OMP-54F28 (FZD8-Fc) in combinations with standard therapy for pancreatic, ovarian and liver cancers, being offered at the CU Cancer Center and elsewhere.

"These are optimistic results for one of the first targeted therapies for cancer stem cells," says Antonio Jimeno, MD, PhD, investigator at the CU Cancer Center, director of the university's Cancer Stem Cell-Directed Clinical Trials Program, and principal investigator of the clinical trial at the CU Cancer Center site. "And it is great to work with such a science-focused sponsor, whose vision aligns with ours: bringing to the clinic cutting-edge drugs and ideas that are focused on targeting CSCs. In the context of the collaboration between the Gates Center for Stem Cell Biology and the CU Cancer Center this was the second clinical trial we offered to our patients with the specific intent to eliminate the CSCs in their tumors."

OMP-54F28 (FZD8-Fc) is an antagonist of the Wnt pathway, a key CSC signaling pathway that regulates the fate of these cells. The Wnt pathway is known to be inappropriately activated in many major tumor types, including colon, breast, liver, lung and pancreatic cancers, and is critical for the function of CSCs. Because of this extensive validation, in the Jimeno lab and elsewhere, the Wnt pathway has been a major focus of anti-cancer drug discovery efforts. OMP-54F28 (FZD8-Fc) and a sister compound also developed by OncoMed, vantictumab (OMP-18R5), are two of the first therapeutic agents targeting t
'/>"/>

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. ChromaDex® Announces Financial Results for the Year Ended 2011
2. Aware, Inc. Reports First Quarter 2012 Financial Results
3. Better housing conditions for zebrafish could improve research results
4. NIH-led study finds genetic test results do not trigger increased use of health services
5. New Tool Helps Drug Developers Optimize Their Research and Target Development for Better Results and a Stronger Competitive Edge
6. Study results: Adult stem cells from bone marrow
7. SF State researcher releases first results from nationwide bee count
8. Aware, Inc. Reports Second Quarter 2012 Financial Results
9. Pilot Results Move GHX Closer to Delivery of Healthcare Industrys First Implantable Device Supply Chain Solution
10. Aware, Inc. Reports Third Quarter 2012 Financial Results
11. Consumers have few negative reactions to the results of genetic testing for cancer mutations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... bacterium that grows in the soil of potato fields can ... a common powerful pesticide used for killing worms on potatoes, ... but lucky for the environment because University of North Carolina ... particular enzyme weren't there, it would take 10,000 years for ...
... come to mind. But they are not the only kind ... as its popular cousin yet its grave situation continues to ... , Sanchez-Azofeifa is the director of the newly ... in the Faculty of Science. The Inter American Institute for ...
... homes and offices is an unaccomplished dream due to the ... The study of photosynthesis in plants could provide new clues ... reaching them, and how they transform it into other forms ... the Freie Universität Berlin, used the X-ray source of the ...
Cached Biology News:New discovery: If it weren't for this enzyme, decomposing pesticide would take millennia 2New discovery: If it weren't for this enzyme, decomposing pesticide would take millennia 3Tropical dry forests receive international recognition 2Plants reveal a secret and bring researchers nearer a cleaner future 2
(Date:7/29/2015)... Madison, NJ (PRWEB) , ... July 29, 2015 , ... ... and approval of combination products , in particular, drug/device combinations. The current system ... innovation by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is ... services. The core expertise of PRC Clinical is focused on Clinical Trial Management, ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... is making good progress in evaluating the full range of capabilities of its ... Adult tissue stem cells perform the day-to-day renewal and repair of normal tissues ...
(Date:7/28/2015)... ... ... Xsample 530 sample changer for vials can be used with Anton Paar density meters, ... 12,000 mPas (internal air) up to 36,000 (external air) – and can process up to ... 530 is its removable magazine, which is easily lifted off its hub and carried by ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4New Moves in Automatic Sample Handling: Introducing Xsample 530 2
... MIT scientists explaining how they recently discovered a catalyst ... assistance of a five-year $20 million award from the ... (Caltech) Chemical Bonding Center (CBC) project, called "Powering the ... fulfill its goal of efficiently and economically converting solar ...
... MEDX ) announced today that it is scheduled to ... a.m. Eastern Time on,Thursday, September 4, 2008. The event ... Investor Relations section of the Medarex website at, http://www.medarex.com ... available,following the event., About Medarex, Medarex is ...
... Sky One,Medical, Inc. ("China Sky One Medical" or "the ... company producing external use,over-the-counter drugs in the People,s Republic ... to list its common stock on the,NASDAQ Global Market., ... the NASDAQ Global Market on,September 15, 2008, and that ...
Cached Biology Technology:Understanding the science of solar-based energy: more researchers are better than one 2Medarex to Present at the Thomas Weisel Partners Healthcare Conference 2China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market 2China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market 3
Request Info...
... Tissue Array (MSTA) slides were designed to study ... from multiple species. Tissue slices from three ... which can then be treated as a single ... in situ hybridization. This format allows ...
... Xcell eukaryotic system, 100 to ... used for electroporation of mammalian ... main unit, CE module for ... square-wave pulses, ShockPod shocking chamber, ...
Request Info...
Biology Products: